KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Receivables (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Change in Receivables for 10 consecutive years, with -$25.0 million as the latest value for Q1 2025.

  • Quarterly Change in Receivables rose 87.5% to -$25.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was -$25.0 million through Dec 2025, up 85.71% year-over-year, with the annual reading at -$25.0 million for FY2025, 85.71% up from the prior year.
  • Change in Receivables hit -$25.0 million in Q1 2025 for CRISPR Therapeutics AG, down from $25.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $200.0 million in Q4 2023 to a low of -$200.0 million in Q1 2024.
  • Historically, Change in Receivables has averaged -$11076.9 across 5 years, with a median of -$17000.0 in 2022.
  • Biggest YoY gain for Change in Receivables was 408263.27% in 2023; the steepest drop was 411664.71% in 2023.
  • Year by year, Change in Receivables stood at $153000.0 in 2021, then tumbled by 132.03% to -$49000.0 in 2022, then soared by 408263.27% to $200.0 million in 2023, then crashed by 87.5% to $25.0 million in 2024, then crashed by 200.0% to -$25.0 million in 2025.
  • Business Quant data shows Change in Receivables for CRSP at -$25.0 million in Q1 2025, $25.0 million in Q4 2024, and -$200.0 million in Q1 2024.